Edesa Biotech prices $25 million public offering of shares and warrants

Edesa Biotech, Inc. (Nasdaq: EDSA), a company with executive offices in Markham, Ontario, Canada¹, announced an underwritten public offering on August 19, 2026. According to the 8-K, on August 19, 2026, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters, for 3,870,500 shares of common shares with accompanying common share warrants to purchase up to 3,870,500 common shares at a combined offering price of $5.50 per share and warrant, and pre-funded warrants to purchase up to an aggregate of 675,000 common shares with accompanying warrants, at a combined price of $5.4999 per pre-funded warrant and warrant.¹

The underwriters also received a 30-day option to purchase up to 681,825 additional common shares and accompanying common share warrants on the same terms as the offering shares.¹ The company said it expects to receive net proceeds of approximately $23.1 million from the offering, after deducting underwriting discounts and commissions and estimated offering expenses.¹ The offering was expected to close on or about August 21, 2026, subject to customary closing conditions.¹

The common share warrants carry an exercise price of $7.50 per share and are exercisable until the earlier of the 18-month anniversary of issuance or the 30th day following the company's public announcement of Phase 2 vitiligo topline data for EB06.¹

Edesa said it intends to use net proceeds for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses.¹ The offering was made under an effective Registration Statement on Form S-3, declared effective by the SEC on September 9, 2025, and a related prospectus supplement dated August 19, 2026.¹